Daniel Sundheim’s MaxCyte MXCT Stock Holding History

Daniel Sundheim’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,510,000	Closed	-$24.5M	–	26
2022 Q1	$24.5M	Hold	3,510,000	–	–	0.29%	24
2021 Q4	$35.8M	Hold	3,510,000	–	–	0.22%	38
2021 Q3	$42.9M	Buy	+3,510,000	New	+$52.9M	0.24%	45

Other funds holding MXCT

Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Daniel Sundheim's MXCT Position: Q2 2022 in Review

Daniel Sundheim sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 3,510,000 shares — an estimated $24.5M sold.

Daniel Sundheim first reported a position in MXCT in Q3 2021 and held it in 3 quarters. The position peaked at $42.9M in Q3 2021. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

Daniel Sundheim reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
Daniel Sundheim sold 3,510,000 MaxCyte shares in Q2 2022, an estimated $24.5M.
Daniel Sundheim first reported a position in MaxCyte in Q3 2021 and held it in 3 quarters.
Daniel Sundheim's MaxCyte position peaked at $42.9M in Q3 2021.
102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on D1 Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.